Genenta Science to Rebrand as Saentra Forge and Enters Defense Sector with A.T.C. Stake, While Suing Enea Tech Biomedical

The latest announcement is out from Genenta Science SpA Sponsored ADR ( (GNTA) ).

In a strategic shift disclosed in a January 27, 2026 SEC filing, Genenta Science outlined plans to change its corporate name to Saentra Forge S.p.A. and its Nasdaq ticker to SAEN, contingent on shareholder approval at an extraordinary meeting scheduled for March 25–26, 2026, aligning its identity with an expanded corporate purpose under Italy’s Golden Power framework. As part of this repositioning, on January 24, 2026 the company signed an investment agreement to acquire an initial 19.5% stake in A.T.C. S.r.l., a private Italian maker of high-precision tactical rifles and special-forces weapon systems, for €1.275 million, with a performance-based path to majority control of up to 51% for a total of €5.1 million and a put option that protects Genenta’s capital if A.T.C. underperforms or loses key licenses. The company also moved to formalize its relationship with Fondazione Praexidia through a five-year renewable shareholders’ agreement signed on January 25, 2026 with CEO and co-founder Pierluigi Paracchi, establishing consultation procedures and a lock-up on their shares for transactions subject to Italy’s Golden Power regime while explicitly leaving management authority with the existing board. Separately, on January 27, 2026 Genenta initiated legal proceedings in the Court of Milan against Fondazione Enea Tech Biomedical over a €20 million convertible bond agreed in March 2025, alleging bad faith and seeking to have the agreement declared null and void and to recover damages after receiving only €7.5 million, a dispute that could affect its financing profile depending on the outcome.

The most recent analyst rating on (GNTA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.

More about Genenta Science SpA Sponsored ADR

Genenta Science S.p.A., a Milan-based clinical-stage biotechnology company focused on developing its lead gene therapy candidate Temferon, is repositioning itself as an industrial aggregator operating across biotechnology, defense, aerospace, cybersecurity and other strategic sectors covered by Italy’s Golden Power national security legislation. The company, which is participated in by Fondazione Praexidia, aims to build a scalable platform for long-term industrial growth by acquiring and integrating high-potential Italian businesses active in national-security regulated industries.

Average Trading Volume: 336,684

Technical Sentiment Signal: Sell

Current Market Cap: $24.89M

Find detailed analytics on GNTA stock on TipRanks’ Stock Analysis page.